These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2514523)

  • 1. [Determinants of income and expenditure development in the annual reports of the health insurance of the Federal Republic of Germany].
    Jacobs K
    Soz Praventivmed; 1989; 34(6):256-9. PubMed ID: 2514523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk structure compensation in Germany's statutory health insurance.
    Busse R
    Eur J Public Health; 2001 Jun; 11(2):174-7. PubMed ID: 11420805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expenditures of The German Statutory Health Insurance for Health Promotion and Disease Prevention 2012-2017: Positive Effects Due To The Disease Prevention Law?].
    Bödeker W; Moebus S
    Gesundheitswesen; 2020 Mar; 82(3):282-287. PubMed ID: 30822817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care cost containment in West Germany.
    Stone DA
    J Health Polit Policy Law; 1979; 4(2):176-99. PubMed ID: 114573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in health care expenditure associated with gaining or losing health insurance.
    Ward L; Franks P
    Ann Intern Med; 2007 Jun; 146(11):768-74. PubMed ID: 17548408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative health systems. The Federal Republic of Germany.
    Henke KD
    Adv Health Econ Health Serv Res Suppl; 1990; 1():145-68. PubMed ID: 10170819
    [No Abstract]   [Full Text] [Related]  

  • 7. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition.
    Busse R; Blümel M; Knieps F; Bärnighausen T
    Lancet; 2017 Aug; 390(10097):882-897. PubMed ID: 28684025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health insurance and health policy in the Federal Republic of Germany.
    Reinhardt UE
    Health Care Financ Rev; 1981 Dec; 3(2):1-14. PubMed ID: 10309554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premium subsidies and social health insurance: substitutes or complements?
    Kifmann M; Roeder K
    J Health Econ; 2011 Dec; 30(6):1207-18. PubMed ID: 21958945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Switching sickness funds and risk compensation mechanisms in the statutory health insurance system in Germany--empirical results from the cooperative health research in the region of Augsburg (KORA)].
    Werner A; Reitmeir P; John J
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S158-66. PubMed ID: 16032535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of public voluntary health insurance on private health expenditures in Vietnam.
    Jowett M; Contoyannis P; Vinh ND
    Soc Sci Med; 2003 Jan; 56(2):333-42. PubMed ID: 12473318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of neural tube defects in Germany.
    Bowles D; Wasiak R; Kissner M; van Nooten F; Engel S; Linder R; Verheyen F; Greiner W
    Public Health; 2014 Mar; 128(3):274-81. PubMed ID: 24559770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-of-illness of psoriasis - results of a German cross-sectional study.
    Jungen D; Augustin M; Langenbruch A; Zander N; Reich K; Strömer K; Thaci D; Purwins S; Radtke M; Gutknecht M
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):174-180. PubMed ID: 28857297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Public expenditure caused by the consumption of illicit drugs in Germany].
    Mostardt S; Flöter S; Neumann A; Wasem J; Pfeiffer-Gerschel T
    Gesundheitswesen; 2010 Dec; 72(12):886-94. PubMed ID: 20066613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Critical Analysis of Obamacare: Affordable Care or Insurance for Many and Coverage for Few?
    Manchikanti L; Helm Ii S; Benyamin RM; Hirsch JA
    Pain Physician; 2017 Mar; 20(3):111-138. PubMed ID: 28339427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can the United States learn from foreign medical insurance systems?
    Reinhardt UE
    Hosp Prog; 1978 Nov; 59(11):60-7. PubMed ID: 100406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are the additional health expenditures generated by insurance bad for society?
    Nyman JA
    Minn Med; 2004 Feb; 87(2):56-9. PubMed ID: 15005130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmaceutical cost of elderly people in private health insurance].
    Wild F
    Versicherungsmedizin; 2009 Dec; 61(4):159-62. PubMed ID: 20052826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Knowledge of "Hardship Exemptions" in statutory sickness insurance].
    Eller M; Baumann F; Mielck A
    Gesundheitswesen; 2002 Nov; 64(11):565-71. PubMed ID: 12442214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.